Ventricular hypertrophy and hypertension: Prognostic elements and implications for management Review uri icon


MeSH Major

  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Hypertension
  • Hypertrophy, Left Ventricular


  • Left ventricular hypertrophy (LVH) is a strong, independent predictor of cardiovascular events and all-cause mortality. Patients with LVH are at increased risk for stroke, coronary heart disease, congestive heart failure, and sudden cardiac death. Hypertension is a major influence on the development of LVH. The prognostic power of LVH is likely multifactorial. LVH represents both a manifestation of the effects of hypertension and other cardiac risk factors over time as well as an intrinsic condition causing pathologic changes in cardiac structure and function. Angiotensin II plays a central role in the development of LVH. Several antihypertensive treatments, especially angiotensin II receptor blockers, can reverse LVH and improve cardiovascular outcomes independent of blood pressure reduction. Further studies are required to determine if these agents should become first-line therapy for all patients with hypertension and LVH.

publication date

  • June 2006



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00059-006-2819-5

PubMed ID

  • 16810470

Additional Document Info

start page

  • 305

end page

  • 16


  • 31


  • 4